Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised H.I.G. Capital on the transaction. H.I.G. Capital, a leading global alternative investment firm with $45 billion of equity capital under management, announced that...
You must be a Standard 1 Year member to access this content.
